Background: Fifteen to thirty percent of AIDS patients develop some type of neurologic disorder during the
Introduction
Fifteen to thirty percent of AIDS patients have neurologic disorders such as HIV-associated dementia (HAD), minor cognitive/motor disorder, HIV-associated myelopathy, and HIV-associated sensory neuropathy (1) . These are among the (HIV-1) preferentially infects CD4+ cells of the peripheral immune system and it also targets CD4+ immune cells of the central nervous system, primarily microglia and perivascular macrophages, early in the course of HIV-1 infection (5, 6) . Despite the occasional infection of astrocytes and the rare infection of neurons (7) (8) (9) (10) , there is cortical neuronal and synaptic loss and dendritic simplification (1 1-13) . Therefore, indirect mechanisms are most likely to be involved in the pathogenesis of HAD (14, 15) . Neuropathologic studies indicate that HAD may be related to levels of unintegrated viral DNA, multinucleated giant cells, positive irnmunostaining for gp4l and p24 (16) , and immunostaining for a unique subset of apoptotic-inducing CD14/CD16-positive and CD14/CD69-positive monocytes (17) . Psychomotor slowing as well as increased levels of cerebrospinal fluid (CSF) ,B2-microglobulin and neopterin and decreased CD4 counts (18) carry an increased risk of progression to dementia (19) .
The severity of HAD may also correlate with the number of HIV-1 -infected macrophages (5, (20) (21) (22) , and CSF RNA viral burden (23) . Recently we showed that levels of gp4l as ascertained by Western blot analysis correlate with the severity of HAD and the levels of immunological nitric oxide synthase (iNOS) (24) . Gp4l is also increased in pediatric patients with progressive neurologic disease (25) . In SIV-infected macaques, neurologic disease correlates with gp41 expression, but not with viral load as detected by viral message (J. Clement and M. C. Zink, personal communication), paralleling observations made in HAD. Expression of mRNA for iNOS, tumor necrosis factor-a (TNF-a), and macrophage inflammatory protein a (MIP-1a) and 1B (MIP-1f) is in close proximity to gp4l-positive cells in HAD patients (26) . MIP-la and MIP-1j are potent chemoattractants for both monocytes and specific subpopulations of lymphocytes. In rodent neuronal/glial and human neuronal aggregate cultures, physiologic subnanomolar concentrations of gp4l induce a cascade of events that is neurotoxic by inducing iNOS-and nitric oxide (NO)-dependent neurotoxicity (24; L. Pulliam, personal communication). Thus, in addition to other viral proteins and host factors, gp41 may play a key role in the pathogenesis of HAD.
The rate of progression of HIV infection to AIDS is influenced by factors including older age (27, 28) , lower CD4+ cell count (27) , decreased hemoglobin, reduced platelet count, and elevated IgA levels and thrush (29) ; however, disease progression is not associated with race, sex, or risk factor for HIV infection (30) . Variations in viral genotype, production by infected macrophages, and subsequent toxin production may contribute to the variability in neuropathology (31) and likewise the variability in neurological progression of HAD. Many studies describing characteristics of HAD looked primarily at cases of rapid progression over a few months, with a mean survival of 3 to 6 months (32-35); few have given attention to differences among variable rates of progression of HAD (36) 1984 and 1994. Seventy-one of these patients were followed until death to obtain information on dementia severity and rate of neurological progression. All of these patients received neurological or neuropsychological examinations within 3 months of death, had a follow-up of >1 month, and had initial Memorial Sloan-Kettering (MSK) scores (38) of <3.
None of these patients had clinical or pathological evidence of pre-existing or concurrent central nervous system (CNS) opportunistic infections, confounding illicit drug use, or pre-existing psychiatric disorders.
Rate of neurological progression was ascertained according to the change in the MSK dementia severity score (38) at initial diagnosis and at death. The criteria for classification of progression rates are described by Bouwman and colleagues (36) in detail and for purposes of brevity are not repeated here. On the basis of these calculated rates of dementia progression, the group was divided into tertiles and compared according to demographic, clinical, and laboratory characteristics. For this study, 11 of these patients were randomly selected, along with HIV-positive, nondemented individuals, for protein analysis of postmortem CNS tissue. The nondemented, slow, moderate, and rapid progression groups each had eight, three, four, and four individuals, respectively. For purposes of statistical power and further assessment of neuropathologic variables associated with severity of dementia, we also combined these immunoblot results with previous findings (24) (39) or HIV-dementia scale (40) , as well as a complete neurological history. These other data are reported in detail elsewhere (36) and are not repeated here.
Immunoblot Analysis
Tissue was collected at autopsy from this prospectively characterized population of AIDS patients, was rapidly frozen in isopentane, and stored at -700C. Cortical specimens were obtained from the mid-frontal gyrus from all patients. In all patients, the presence of CNS opportunistic infections or lymphoma was excluded by computed tomography (CT) or magnetic resonance imaging (MRI) and CSF analysis, as well as by postmortem histopathologic evaluation of brain tissue sections. HIV-1 -seronegative control specimens were obtained from patients without CNS lesions and have been previously reported (24) . The causes of death in control patients included myocardial infarction, trauma, cirrhosis of the liver, atherosclerosis, and widespread cytomegalovirus infection.
Immunoblot analysis of iNOS, HAM56, gp4l, p24, gpl20, and ,3-tubulin was performed as described previously (24) . Briefly, tissues were homogenized in ice-cold 50 mM Hepes (pH 7.4) with 1 mM ,B-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamide, leupeptin (10,tg/ml), pepstatin A (10 ,g/ml), aprotinin (1 ,ug/ml), and 1 mM EDTA, and centrifuged at 100,000 X g for 60 min. Five to sixteen percent gradient polyacrylamide gel electrophoresis (PAGE) was used to separate pro- (24) and divided the combined results into three groups on the basis of MSK score at time of death (Table 2) . These groups consisted of MSK scores of 0, 1 to 2, and 3 to 4, and showed no significant difference Fig. 2C ). We next evaluated iNOS/,3-tubulin ratios with MSK scores and combined these data with our previous patient cohort (24) . We confirmed and strengthened our original observations, which showed a significant correlation between iNOS protein expression and the severity of HAD as measured by MSK scores (p = 0.618, p < 0.001; Fig. 2D ).
The relative level or extent of macrophage or microglial activation was assessed by Western blot analysis of HAM56, a marker that is widely (Fig. 3A, B) . Correlation analysis yielded a moderate but significant positive correlation between HAM56 protein expression and HAD progression (p = 0.502, p < 0.027; Fig. 3C ). HAM56/f3-tubulin ratios were also compared with MSK scores; this comparison included our previous patient cohort (24) . We observed a strong and significant correlation between HAM56 levels and the severity of HAD (p = 0.700, p ' 0.001; Fig. 3D ). (24) .
The HIV-1 viral proteins gp4l, gpl20, and p24 levels were also examined via immunoblotting and compared with rate and severity of progression. As in previous reports (24, 41, 42) , we were unable to detect gpl20. Like iNOS and HAM56 protein expression, significantly elevated levels of gp4l protein were found in rapid progressors (Fig. 4A, B) . Correlation analysis showed a significant correlation between the progression of HAD and gp41/13-tubulin ratios (p = 0.564, p < 0.017; Fig. 4C ). In the comparison of MSK scores with gp41/p-tubulin ratios we again combined data from this study with those from our previous patient cohort (24) . Fig. 5 ).
Discussion
In the present study we show that the severity and rate of progression of HAD correlates significantly with levels of the HIV-1 coat protein, gp4l, iNOS, and HAM56, a marker of microglial/ macrophage activation. Our observations extend and strengthen our previous studies in which we showed that only the severity of HAD correlated with indices of immune system activation (5) and with levels of iNOS and gp4l (24) . Other investigators have observed mRNA or protein for iNOS (24, 26, 43) 10O. infected patients (24 Previous studies have shown a wide variability in the rates of progression of HAD among HIV-infected individuals (2, 20, 36, 45) . We have previously identified unique groups within this spectrum which we designated non-, moderate, and rapid progressors (36 (24) .
progressors have a very slow neurological progression over a course of months to years, whereas the rapid progressors show rapid increases in neurological severity over weeks to months (36) . One limitation in our data is that the rate of neurological progression was determined from only two MSK scores, assuming a linear change. Such an assumption easily overlooks a stepwise or multiphasic change, e.g., an initially slow change followed by a rapid change. Prior studies have indicated that there is no difference in progression to AIDS according to sex, race, or risk factor for HIV infection (30, 45) , whereas others have shown a difference according to race, risk factor, CD4 count, and survival to death (46 (51) , while expression of Pr55gag inhibits internalization and degradation of gp4l (52) . In the CNS where viral replication and maturation is slowed, gp41 will not be lost due to the production of viral particles, and if degradation is inhibited by expression of Pr55gag, then it is feasible that gp4l would accumulate, perhaps in relation to soluble HIV proteins that would be exposed to proteolytic processes.
In vitro studies in both rodent and human glial cultures indicate that full-length and appropriately post-translationally modified gp41 expressed on cellular membranes by vesicular stomatitis virus (VSV) is a potent inducer of TNF-a, IL-1X3, and iNOS (53, 54) . Interestingly, recombinant bacterially expressed gp4l containing the extracellular domain obtains appropriate tertiary structure (55, 56) and behaves in an identical manner to full-length gp4l in inducing TNF-a, LL-1B, and iNOS (24, 54, 57) . Thus, the elevated levels of gp4l in severe and rapidly progressing HAD may act as an activator of the immune system and elicit a sustained immunologic reaction that triggers pathogenic processes, ultimately leading to severe and rapid progression of HAD. Consistent with this notion is our observation that subnanomolar physiologically relevant concentrations of recombinant gp4I is neurotoxic to rodent cultures and kills neurons in an NO-dependent fashion from induction of iNOS (24, 57) . Recent studies indicate that recombinant gp4l is also toxic to human neuronal cultures in an iNOS/NO-dependent fashion (L. Pulliam, personal communication) . We propose that, like nonsecreted membrane proteins that induce signaling processes through cell-to-cell interactions, the extracellular portion of gp4l expressed in infected cells interacts with adjacent cells to cause macrophage/microglial activation and induction of iNOS. This is particularly important in the latter stages of HAD. Strategies aimed at reducing levels of gp41 or interfering with signaling cascades induced by gp4l may have therapeutic benefit.
